Patient
-
Courtesy of Sarepta
Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades
The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also enduring tragic risk.
By Michael Gibney • March 20, 2025 -
Stock via Getty Images
Pricing transparency is in the spotlight — and that could be good news for drugmakers
An opaque system of rebates and discounts makes understanding a drug’s true price near impossible, even for experts. Can efforts to bring transparency into that system now pan out?
By Michael Gibney • March 11, 2025 -
Explore the Trendline➔
Stock via Getty Images
TrendlineRare diseases
As drug developers find promise in the rare diseases, deals and treatments are on the rise
By PharmaVoice staff -
elements.envato.com/drazenphoto
Sponsored by Noble InternationalNavigating human errors in medical device usage: Insights from human factors research
Even the most advanced medical devices can fail patients if used incorrectly. These are the most common errors.
By Samantha Colangelo, M.S. • March 10, 2025 -
Kevin C. Cox via Getty Images
The top 3 impacts of Trump’s health data purge
Interrupted access to health-related data has already led to worse outcomes and could undermine faith in the U.S. healthcare system, experts say.
By Michael Brady • March 6, 2025 -
Stock via Getty Images
Americans want to participate in clinical trials — so why don’t they?
A recent study revealed the key barriers to enrollment and how pharma can help turn the tide.
By Kelly Bilodeau • March 4, 2025 -
Permission granted by ixlayer
Sponsored by ixlayerTransforming biopharma’s approach to patient engagement with direct-to-patient programs
Consumers want more from biopharma. Next-generation direct-to-patient programs can deliver.
By Matthew Walsh, General Manager, Biopharma, ixlayer • March 3, 2025 -
Permission granted by Teva
Teva targets schizophrenia to build on innovative medicines growth
The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.
By Meagan Parrish • Feb. 28, 2025 -
Getty Images via Getty Images
Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide
Orphan drug development has long been incentivized by government policy. But as the financial math shifts, so do the risks of bringing rare disease drugs to market.
By Michael Gibney • Feb. 25, 2025 -
Sarah Silbiger via Getty Images
In FDA job cuts, experts see threat of far-reaching impact
"Any place that gets cut, it's going to have an impact, because there's not any spare personnel at FDA,” said former agency commissioner Robert Califf, of the layoffs.
By Jonathan Gardner , Delilah Alvarado • Feb. 21, 2025 -
Stock via Getty Images
The kids are alright: How pharma can make inroads with Gen Z
As drug development priorities shift, pharma companies need to understand younger patients to improve their reputation.
By Amy Baxter • Feb. 12, 2025 -
Stock via Getty Images
Are orexins the next golden child of neuroscience?
An emerging class of orexin-based drugs are on the cusp of disrupting care for sleep disorders — and potentially much more.
By Meagan Parrish • Feb. 10, 2025 -
Permission granted by Vertex Pharmaceuticals
Deep DiveA new, non-opioid pain drug is here. Getting it to patients could be agony.
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful biotechs contend with a healthcare system that’s long favored opioids?
By Jacob Bell • Feb. 3, 2025 -
Stock via Getty Images
Year in PreviewPharma’s forecast for 2025: Sowing seeds of a rebound
Despite regulatory uncertainty, pharma is bouncing back from a market slump and is being fueled by innovation.
By Meagan Parrish • Jan. 31, 2025 -
Stock via Getty Images
Gene therapies have been uneven for DMD — but these companies hope to turn the tide
Despite mixed results using gene therapies to treat Duchenne muscular dystrophy, drug developers are pushing ahead with the belief the answer could come down to delivery.
By Meagan Parrish • Jan. 24, 2025 -
iStock.com/jarenwicklund
Sponsored by Accessia HealthBeyond copays: Redefining assistance for those with rare diseases and chronic conditions
Accessia Health helps ease the burden of managing a rare disease or chronic condition.
Jan. 21, 2025 -
Anna Moneymaker via Getty Images
Musk’s rare disease torpedo, hospitals’ pharma fix and other policies leaders are tracking
There’s more to pharma's regulatory story in 2025 than just the IRA.
By Meagan Parrish • Jan. 17, 2025 -
Stock via Getty Images
Opinion // Year in PreviewPharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials
Coming changes that could impact pharma from drug development to launch.
By Meagan Parrish • Jan. 10, 2025 -
iStock via Getty Images
Subcutaneous options offer convenience for patients — and a valuable window for drugmakers
New formulations for under-the-skin application of drugs give pharmas another opening in a crowded market.
By Kelly Bilodeau • Jan. 7, 2025 -
Stock via Getty Images
10 of our most read articles of 2024
The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.
By Meagan Parrish • Dec. 20, 2024 -
PeopleImages via Getty Images
Maternal mortality trends remain dire — and researchers face an uphill battle to solve them
Rising maternal mortality, particularly among vulnerable populations, stems in part from a lack of research in pregnant women.
By Michael Gibney • Dec. 17, 2024 -
Courtesy of Roche
3 closely watched drugs that failed in the clinic
How recent setbacks and scattered successes could impact various sectors of the industry.
By Kelly Bilodeau • Dec. 16, 2024 -
Stock via Getty Images
Will the ‘anti-woke’ movement derail DEI efforts in pharma?
Amid the DEI backlash in corporate America, pharma leaders are quietly adjusting tactics.
By Meagan Parrish • Dec. 13, 2024 -
Pony Wang via Getty Images
Deep DiveEndometriosis drug research, long underfunded, confronts familiar problems in women’s health
Despite the disease’s prevalence, endometriosis remains misunderstood, and research into drugs that might treat it draws scant funding — problems that have deep roots.
By Delilah Alvarado • Dec. 11, 2024 -
Permission granted by Alexion/AstraZeneca
How Alexion markets a rare disease drug by ‘starting with the end in mind’
The biopharma, now an arm of AstraZeneca, needs to build the plane while flying it to be first in rare diseases with no other option.
By Michael Gibney • Dec. 3, 2024 -
Stock via Getty Images
Can the girl power of Arrivo’s depression drug help reverse its fortunes?
After failing a mid-stage trial, the biotech shifted course and is now targeting females with the goal of proving gender can play a role in depression outcomes.
By Kelly Bilodeau • Dec. 3, 2024
